Beruflich Dokumente
Kultur Dokumente
Intercalating Mitosis
agents
Spindle poisons
Prinsip Dasar
• Mencegah sel kanker untuk bermultiplikasi,
menginvasi, metastasis dan membunuh
penderitanya
• Mempengaruhi multiplikasi sel dan
pertumbuhan tumor, terutama sel yang
pertumbuhannya cepat
• Pemberian yang efektif: efikasi maksimal
dengan efek samping seminimal mungkin
Principle Of Chemotherapy
Chemotherapy
Alopecia
Mucositis
Pulmonary fibrosis
Cardiotoxicity
Nausea/vomiting
Local reaction
Diarrhea
Renal failure
Cystitis
Myelosuppression
Sterility
Phlebitis
Myalgia
Neuropathy
Targeted Therapy
Targeted Therapy
• Cisplatin +vinorelbine
• Cisplatin+etoposide
• Cisplatin+vinblastin
• Cisplatin+Gemcitabine
• Cisplatin+Docetaxel
• Carboplatin +Paclitaxel
Mekanisme Aksi Agen Sitotoksik pada Level
Siklus Sel
Antibiotics
Antimetabolites
S
(2-6h)
G2
(2-32h) Vinca alkaloids
M
(0.5-2h) Mitotic inhibitors
G1
(2- h)
G0
Kemoterapi Kombinasi
Kemoterapi
kombinasi penting
utk mencapai log
kill dimana
populasi sel tumor
tidak sensitif thd
obat tunggal
Tujuan Kemoterapi
Kombinasi
Meningkatkan Efikasi
Aktivitas Keamanan
Selective affinity
Weak affinity
for mitotic spindle for axonal
microtubules microtubules
Palliative CT
Adjuvant CT CT+RT
Platinum-based or
Pre-operative CT combination
Platinum-free regimens
0.75
0.50
Obs
0.25
NVB + CDDP
0
0 20 40 60 80 100 120
months
ANITA 13
80 80
+5.3%
61.0
+8.9%
60 60
55
Survival (%)
Survival (%)
48.8
40 57.1 40
46.1
43.5
20 20
0 0
p=0.004 p=0.0007
0 1 2 3 4 5 ≥6 0 1 2 3 4 5 ≥6
• 5 trials • 4 trials
• Absolute survival benefit of 5.3% at 5-years • Absolute survival benefit of 8.9% at 5-years
Pignon, ASCO 2006 Douillard, ESMO 2006- ICACT 2007
Phase II study
n= 56 NAVELBINE D1, D8 30 mg/m²
IIIA 36%, IIIB 64% CISPLATIN D1 80 mg/m²
every 3 weeks
OR 54%
Resection rate 77%
Complete resection 32% (27% T4 – 50% N3)
MS 21.5 m
1-YS 89% (Compl. Res.) vs 45% (Incompl. Res.)
2-YS 61% (Compl. Res.) vs 10% (Incompl. Res.)
Spasova, Neoplasma 02
Palliative CT
Adjuvant CT CT+RT
Platinum-based or
Pre-operative CT combination
Platinum-free regimens
Randomised study
n=102
NVB +CDDP NVB+CDDP + RT (60 Gy)
IIIA 15%
IIIB 85% then RT (60 Gy) then NVB+CDDP
OR 47% 80%
CR 17% 21%
Esophagitis 4% 18%
Nausea/Vomiting 15% 39%
Neurotoxicity 2% 4%
Pulmonary toxicity 2% 4%
Zatloukal, Lung Cancer 2004
Palliative CT
Adjuvant CT CT+RT
Platinum-based or
Pre-operative CT combination
Platinum-free regimens
Phase III study 1st line: NVB+CDDP q3w* 1st line: GEM+CDDP q3w*
n=272 2nd line: GEM weekly 2nd line: NVB weekly
Efficacy
OR 1st Line 32.1% 26.7%
MS 11m 11m
Toxicity (Gr 3-4, %pts)
Neutropenia 30.7% (p= 0.017) 17.7%
Thrombopenia 0% (p= 0.004) 9.3%
Cost
Total direct costs 882 € (p< 0.0001) 2,900 €
per patient
Martoni, Eur. J. Cancer 2005
*Followed by maintenance of the same drug NVB or GEM as in a single agent
for responding and stable disease patients
OR (ITT) 20.8%
Disease control 66%
MS 8.6 m
1-YS 34.4%
Tan, Lung Cancer 2005
Tolerance %pts
NAVELBINE + CBDCA n MS
NVB+CBDCA:
An effective outpatient chemotherapy
Quality of life of NAVELBINE + CDDP/CBDCA
25 25
0 0
NAVELBINE + CDDP NAVELBINE + CBDCA
(n=202) (n=111)
Kelly, JCO 2001 Tan, Lung Cancer 2005
No need of rehabilitation:
- complete functional independence (ADL, IADL) Poly CT can be feasible
- negligible co-morbidity
Reversible with rehabilitation:
- dependence in ADL Mono CT should be preferred
- function limiting co-morbidity
Irreversible:
- dependence in ADL BSC is the best option
- severe co-morbidity
Adapted from Balducci, Management of Cancer in the older person: a practical approach; The Oncologist 2000
Gridelli, JNCI 99
Gridelli, JNCI 99
Phase II study
n= 33 NAVELBINE D1, D8, D15 30 mg/m²
St IIIA, IIIB, IV CISPLATIN D1, D8, D15 25 mg/m²
Median age= 73 q4 weeks
OR 48%
Disease control 77%
Median duration response 7m
MS 11 m
Cinical benefit 46% responders
Neutropenia Gr 3-4 44.5% pts including 1 toxic death
(PS2 / infection)
Mattioli, ESMO 02
OR 31%
Disease control 67%
PFS 6.7 m
MS 8.8 m
Neutropenia Gr 3-4 28%
Febrile neutropenia 4%
Thrombocytopenia Gr 3-4 8%
Fatigue None
Neurotoxicity 3%
Depperman, ESMO 2004
NVB+CDDP
NVB+CDDP NVB+CDDP+RT
NVB+CBDCA
Adjuvant or Sequential and
NVB single agent
Pre-operative CT concomitant
Palliative CT
As a single-agent:
30 mg/m²/w
In combination:
25-30 mg/m² D1, D8 every 3 weeks